Steven Cohen's NRIX Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 3.21 M shares of Nurix Therapeutics, Inc. (NRIX) worth $60.93 M, representing 0.07% of the portfolio. First purchased in 2021-Q4, this medium-term investment has been held for 14 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in NRIX, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2025, adding 3.49 M shares. Largest reduction occurred in Q3 2025, reducing 832,097 shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Nurix Therapeutics (NRIX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Nurix Therapeutics (NRIX) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +340,183 | Add 11.85% | 3.21 M | $18.97 |
| Q3 2025 | -832,097 | Reduce 22.47% | 2.87 M | $9.24 |
| Q2 2025 | +3.49 M | Add 1595.37% | 3.7 M | $11.39 |
| Q1 2025 | -654,506 | Reduce 74.98% | 218,453 | $11.88 |
| Q4 2024 | +872,959 | New Buy | 872,959 | $18.84 |
| Q2 2024 | -9,500 | Sold Out | 0 | $0.00 |
| Q1 2024 | +9,500 | New Buy | 9,500 | $14.70 |
| Q4 2023 | -1,114 | Sold Out | 0 | $0.00 |
| Q3 2023 | +1,107 | Add 15814.29% | 1,114 | $7.86 |
| Q2 2023 | -9,594 | Reduce 99.93% | 7 | $9.57 |
| Q1 2023 | +9,601 | New Buy | 9,601 | $8.88 |
| Q2 2022 | -69,850 | Sold Out | 0 | $0.00 |
| Q1 2022 | -66,700 | Reduce 48.85% | 69,850 | $14.02 |
| Q4 2021 | +136,550 | New Buy | 136,550 | $28.95 |
Steven Cohen's Nurix Therapeutics Investment FAQs
Steven Cohen first purchased Nurix Therapeutics, Inc. (NRIX) in Q4 2021, acquiring 136,550 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Nurix Therapeutics, Inc. (NRIX) for 14 quarters since Q4 2021.
Steven Cohen's largest addition to Nurix Therapeutics, Inc. (NRIX) was in Q2 2025, adding 3,703,594 shares worth $42.18 M.
According to the latest 13F filing for Q4 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 3,211,680 shares of Nurix Therapeutics, Inc. (NRIX), valued at approximately $60.93 M.
As of the Q4 2025 filing, Nurix Therapeutics, Inc. (NRIX) represents approximately 0.07% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Nurix Therapeutics, Inc. (NRIX) was 3,703,594 shares, as reported at the end of Q2 2025.